Live biotherapeutic/Microbiome Based Therapeutics Market Size, Share & Trends Analysis Report By Product (VOWST (SER-109), REBYOTA, Visbiome, Other Pipeline Products), By Route of Administration (Oral Therapeutics, Rectal Therapeutics), By Target Disease Indication (Recurrent C. Difficile Infection, Dietary Management of Microbial Imbalance, Other Indications), By Distribution Channel, By End User, By Region, And Segment Forecasts, 2025-2034

Report Id: 1300 Pages: 180 Last Updated: 22 May 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation Of Live biotherapeutic/Microbiome Based Therapeutics Market

Live biotherapeutic/Microbiome Based Therapeutics Market By Product

  • VOWST (SER-109)
  • REBYOTA
  • Visbiome
  • Other Pipeline Products

Live biotherapeutic/Microbiome Based Therapeutics Market By Route Of Administration

  • Oral Therapeutics
  • Rectal Therapeutics

Live biotherapeutic/Microbiome Based Therapeutics Market By Target Disease Indication

  • Recurrent C. Difficile Infection
  • Dietary management of microbial imbalance
  • Other Indications

Live biotherapeutic/Microbiome Based Therapeutics Market By Distribution Channel

  • Direct Sales
  • Pharmacies
  • Online Platforms

Live biotherapeutic/Microbiome Based Therapeutics Market By End User

  • Healthcare Facilities
  • Home Healthcare

Live biotherapeutic/Microbiome Based Therapeutics Market By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Live biotherapeutic/Microbiome Based Therapeutics Market, by Country, 

  • U.S.
  • Canada

Europe Live biotherapeutic/Microbiome Based Therapeutics Market, by Country,

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market, by Country,

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Live biotherapeutic/Microbiome Based Therapeutics Market, by Country, 

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market, by Country, 

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Live biotherapeutic/Microbiome Based Therapeutics Market Snapshot

Chapter 4. Global Live biotherapeutic/Microbiome Based Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Live biotherapeutic/Microbiome Based Therapeutics Market Industry Trends
4.10. Global Live biotherapeutic/Microbiome Based Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034

Chapter 5. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. Market Share by Product, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:

5.2.1. VOWST (SER-109)
5.2.2. REBYOTA
5.2.3. Visbiome
5.2.4. Other Pipeline Products

Chapter 6. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 2: By Route of Administration, Estimates & Trend Analysis
6.1. Market Share by Route of Administration, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:

6.2.1. Oral Therapeutics
6.2.2. Rectal Therapeutics

Chapter 7. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 3: Target Disease Indication, Estimates & Trend Analysis
7.1. Market Share by Target Disease Indication, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Target Disease Indication:

7.2.1. Recurrent C. Difficile Infection
7.2.2. Dietary management of microbial imbalance
7.2.3. Other Indications

Chapter 8. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 4: By Distribution Channel, Estimates & Trend Analysis
8.1. Market Share by Distribution Channel, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:

8.2.1. Direct Sales
8.2.2. Pharmacies
8.2.3. Online Platforms

Chapter 9. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 5: By End User, Estimates & Trend Analysis
9.1. Market Share by End User, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End User:

9.2.1. Healthcare Facilities
9.2.2. Home Healthcare

Chapter 10. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Live biotherapeutic/Microbiome Based Therapeutics Market, Regional Snapshot 2024 & 2034

10.2. North America
10.2.1. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.2.3. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route Of Administration, 2021-2034
10.2.4. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indication, 2021-2034
10.2.5. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.2.6. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034

10.3. Europe
10.3.1. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.3.3. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route Of Administration, 2021-2034
10.3.4. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indication, 2021-2034
10.3.5. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.3.6. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034

10.4. Asia Pacific
10.4.1. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.4.3. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route Of Administration, 2021-2034
10.4.4. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indication, 2021-2034
10.4.5. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.4.6. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034

10.5. Latin America
10.5.1. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.5.3. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route Of Administration, 2021-2034
10.5.4. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indication, 2021-2034
10.5.5. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.5.6. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034

10.6. Middle East & Africa
10.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.6.3. Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route Of Administration, 2021-2034
10.6.4. Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indication, 2021-2034
10.6.5. Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.6.6. Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034

Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles

11.2.1. Seres Therapeutics, Inc.

11.2.1.1. Business Overview
11.2.1.2. Key Solution/Service Overview
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy

11.2.2. 4D Pharma
11.2.3. Adiso Therapeutics
11.2.4. Alveolus Bio Inc
11.2.5. AOBiome Therapeutics, Inc.
11.2.6. Assembly Biosciences
11.2.7. Azitra
11.2.8. Biomica
11.2.9. Destiny Pharma
11.2.10. Destiny Pharma plc
11.2.11. EnteroBiotix Limited
11.2.12. Finch Therapeutics
11.2.13. Infant Bacterial Therapeutics AB
11.2.14. MaaT Pharma
11.2.15. Microbiotica
11.2.16. OSEL INC.
11.2.17. OxThera
11.2.18. Scioto Biosciences, Inc.
11.2.19. Second Genome
11.2.20. Seres Therapeutics
11.2.21. Servatus Limited
11.2.22. Siolta Therapeutics
11.2.23. Vedanta Biosciences
11.2.24. YSOPIA Bioscience
11.2.25. Other prominent player

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
1578
Security Code field cannot be blank!

Frequently Asked Questions

4D Pharma, Adiso Therapeutics, Alveolus Bio Inc, AOBiome Therapeutics Inc, Assembly Biosciences, Azitra, Biomica, Destiny Pharma, Destiny Pharma plc,

The Live Biotherapeutic Product (LBP) Market is expected to grow at a 7.04% CAGR during the forecast period for 2025-2034.

Product, Target Disease Indication, and Route Of Administration are the key segments of the Live Biotherapeutic Product (LBP) Market.

North American region is leading the Live Biotherapeutic Product (LBP) Market.

Live biotherapeutic/Microbiome Based Therapeutics Market Size is valued at USD 73.25 Bn in 2024 and is predicted to reach USD 142.81 Bn by the year 20

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying